Skip to main content

Comparison of venous and HePTFE tibial and peroneal bypasses in critical limb ischemia patients unsuitable for endovascular revascularization

Uhl et al. 20151

Department of Vascular Surgery, Krankenhaus Barmherzige Brüder, Regensburg, Germany

Primary patency of GORE® PROPATEN® Vascular Graft

N=89
1 year 64%
2 years 49%
3 years 34%

 

 

 

 


Patient characteristics*

Characteristic N %
Rutherford classification  
4 23 26%
5 66 74%
6 7 8%
CLI 89 100%
Hypertension 80 90%
Diabetes 41 46%
Renal insufficiency 41 46%
Prior operation 43 48%
Distal anastomotic vessel  
TP trunk 4 5%
Anterior tibial 52 67%
Posterior tibial 12 15%
Peroneal artery 10 13%

Study details

  • Retrospective, non-randomized, single-center analysis of prospectively collected data
  • GORE® PROAPTEN® Vascular Graft was utilized in patients lacking an adequate autologous vein (diameter less than 3 mm or more than two vein segments required to achieve needed length)
  • 30-day mortality and major amputation rates were both 7%
  • Survival rates at one year and three years were 77% and 47%, respectively

The results of our study show that autologous vein grafts are still first choice for tibial and peroneal bypasses in patients with critical limb ischemia. If no adequate vein is available, heparin-bonded expanded polytetrafluoroethylene bypasses are an acceptable alternative to an otherwise impending major amputation. – C. Uhl


1. Uhl C, Hock C, Betz T, Greindl M, Töpel I, Steinbauer M. Comparison of venous and HePTFE tibial and peroneal bypasses in critical limb ischemia patients unsuitable for endovascular revascularization. Vascular 2015;23(6):607-613.